ストックスクリーナーアプリを入手
8.15
1.12%
0.09
アフターアワーズ：
8.18
0.03
+0.37%
前日終値:
$8.06
開ける：
$8
24時間の取引高:
249.29K
Relative Volume:
1.10
時価総額：
$517.04M
収益：
-
当期純損益:
$-159.39M
株価収益率:
-2.3022
EPS:
-3.5401
ネットキャッシュフロー:
$-105.22M
1週間 パフォーマンス:
+35.49%
1か月 パフォーマンス:
+14.47%
6か月 パフォーマンス:
-2.16%
1年 パフォーマンス:
-39.76%
1日の値動き範囲:
$7.88
$8.2466
1週間の範囲:
$5.91
$8.61
52週間の値動き範囲:
$4.77
$14.71
Abivax Adr Stock (ABVX) Company Profile
ABVX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ABVX
Abivax Adr
|
8.15 | 381.57M | 0 | -159.39M | -105.22M | -3.5401 |
|
ONC
Beone Medicines Ltd Adr
|
257.00 | 26.69B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.82 | 114.81B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.282 | 41.83M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
85.54 | 6.60B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
483.07 | 65.36B | 14.09B | 4.50B | 2.96B | 39.28 |
Abivax Adr Stock (ABVX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-20 | 開始されました | Morgan Stanley | Equal-Weight |
| 2024-12-04 | 開始されました | JMP Securities | Mkt Outperform |
| 2024-07-29 | 開始されました | Laidlaw | Buy |
| 2024-05-20 | 開始されました | BTIG Research | Buy |
| 2024-04-29 | 開始されました | Guggenheim | Buy |
| 2024-04-29 | 開始されました | Piper Sandler | Overweight |
| 2023-11-14 | 開始されました | Leerink Partners | Outperform |
| 2023-11-14 | 開始されました | Morgan Stanley | Equal-Weight |
すべてを表示
Abivax Adr (ABVX) 最新ニュース
Promising Outlook for Abivax’s Obefazimod in Ulcerative Colitis with Upcoming Phase 3 Results as Key Catalyst - TipRanks
Abivax SA Reports Increased Losses Amid R&D Expansion - TipRanks
Abivax Reports First Quarter 2025 Financial Results with Increased R&D Costs - TipRanks
Abivax Presents First Quarter 2025 Financial Results - GlobeNewswire Inc.
Optimistic Buy Rating for Abivax SA: Obefazimod’s Potential in Ulcerative Colitis and Market Opportunity - TipRanks
Abivax Completes Enrollment for Phase 3 Ulcerative Colitis Trials - TipRanks
Abivax Announces AGM Details and Board Appointment Amid 2025 Milestones - TipRanks
Abivax ADR (NASDAQ: ABVX) – Does It Provide Stability And Growth? - Stocksregister
Abivax Reports 2024 Financial Results, Eyes Clinical Milestones - TipRanks
Abivax SA: Promising Clinical Developments and Positive Outlook Justify Buy Rating - TipRanks
Promising Prospects for Abivax: Buy Rating Backed by Clinical Progress and Financial Strength - TipRanks
Abivax SA’s Obefazimod: A Promising Blockbuster in Ulcerative Colitis Treatment - TipRanks
Positive Outlook for Abivax: Buy Rating Supported by Promising Phase 3 Trials and Strong Financial Position - TipRanks
Abivax’s Obefazimod: A Promising New Treatment for Ulcerative Colitis with Phase 3 Data Anticipated in 2025 - TipRanks
Buy Rating for Abivax: Promising Potential of Obefazimod in Ulcerative Colitis Treatment - TipRanks
Wall Street Analysts See a 360.53% Upside in Abivax SA Sponsored ADR (ABVX): Can the Stock Really Move This High? - MSN
Is Boston Scientific (BSX) Outperforming Other Medical Stocks This Year? - Nasdaq
Wall Street Analysts Think Abivax SA Sponsored ADR (ABVX) Could Surge 427.9%: Read This Before Placing a Bet - Yahoo Finance
Potential Price Increase for Abivax ADR (ABVX) After Recent Insider Activity - Knox Daily
Sibanye Stillwater Limited ADR (SBSW) rating downgrades by HSBC Securities - Knox Daily
Quantum Corp (QMCO) Stock: A Closer Look at the Market Potential - The News Heater
Analyzing the Price-to-Earnings Ratio of Abivax ADR (ABVX) - The News Heater
Capricor Therapeutics Inc (CAPR) Shares Plummet Below 1-Year High - The News Heater
Paylocity Holding Corp’s (PCTY) Stock: A Long-Term Performance Analysis - The News Heater
Perrigo Company plc (PRGO) Stock: A Closer Look at the Moving Averages - The News Heater
Analyzing the Price-to-Earnings Ratio of ICL Group Ltd (ICL) - The News Heater
Tectonic Therapeutic Inc (TECX) Stock: A Review of the Recent Movement - The News Heater
Healthcare Triangle Inc (HCTI) Stock: A Closer Look at the Market Potential - The News Heater
Here's Why Abivax SA Sponsored ADR (ABVX) is Poised for a Turnaround After Losing -19.81% in 4 Weeks - MSN
Abivax Initiates $150 Million ATM Program on Nasdaq - TipRanks
Abivax Reports Strong Q3 Financials and Clinical Progress - TipRanks
Abivax SA Unveils New Ulcerative Colitis Treatment Data - TipRanks
Abivax ADR receives Investment Bank Analyst Rating Update By Investing.com - Investing.com
Citi Appointed as Depositary Bank for Abivax SA’s ADR Program - Business Wire
Abivax Adr (ABVX) 財務データ
収益
当期純利益
現金流量
EPS
0.86%
1.24%
大文字化:
|
ボリューム (24 時間):